Diabetes Mellitus (DM) and tuberculosis (TB) are two major and increasingly connected global health problems. DM affects around one in ten adults worldwide and its prevalence is increasing rapidly, especially in sub-Saharan Africa. TB remains the leading cause of death from a single infectious agent, killing 1.6 million people in 2022. People living with DM are at much higher risk of developing TB and having poor TB outcomes, including death, treatment failure, and recurrence. This makes global TB control efforts even harder and puts a growing health and socioeconomic burden on already overwhelmed health systems.
Despite the scale of the problem, there are major gaps in evidence to guide prevention and care. Thus far, research has largely focused on describing the link between DM and TB. In contrast, there is only little evidence on how to prevent TB in people with DM or how best to manage this combined condition. There are no randomized controlled trials assessing the efficacy, safety, or cost-effectiveness of TB preventive treatment in people with DM. Moreover, there is limited information on the quality of care for DM and DM-TB in sub-Saharan Africa, making it difficult for policymakers to design effective and efficient responses.
The overall objective of the PROTID project is to address these gaps by generating high-quality evidence to inform policy and practice. PROTID is the first global randomized controlled trial to evaluate TB preventive therapy in people with DM, assessing its efficacy, safety, cost-utility, and potential impact at the population level. Alongside the trial, the project examines gaps in diagnosis, treatment, and quality of care for DM and DM-TB in Uganda and Tanzania, with the aim of identifying practical improvements that can be implemented within existing health systems.
The project’s pathway to impact is through evidence-based policy change and improved clinical practice. By providing robust trial data and real-world health system evidence, PROTID will support the development of international guidelines and national strategies for TB prevention in people with DM. The results are expected to contribute to reduced TB incidence, illness, and deaths among people with DM, more efficient use of health resources, and stronger integration of communicable and non-communicable disease care. This impact is particularly significant in Africa, where the dual burden of DM and TB is growing rapidly, and in Europe among migrants and eastern European populations with high risk of both conditions.